{"id":408312,"date":"2021-01-05T07:33:27","date_gmt":"2021-01-05T12:33:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408312"},"modified":"2021-01-05T07:33:27","modified_gmt":"2021-01-05T12:33:27","slug":"mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/","title":{"rendered":"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">DENVER, Jan.  05, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SyPIJBdyCAng_lCik3lNFIv0aOclHKfcMbV8_SF5aIGLRrfiF6dsbFJVwCh3qDEmYoQzH2kSn_AGbAI5RV52ktluM3CKtbruNCmFpBTlPJU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Mydecine Innovations Group<\/u><\/a> (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (\u201cMydecine\u201d or the \u201cCompany\u201d), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: \u201cThe neurocognitive effects of low dose psychoactive substances,\u201d at Australia\u2019s Macquarie University<\/p>\n<p>The research, led by Principal Investigator Dr. Vince Polito, Senior Research Fellow at the Department of Cognitive Science at Macquarie University, is the first study of naturalistic microdosing in a lab setting. Previous studies have either relied on surveys of microdosers or have given people who have not microdosed before a single controlled dose. In this study people who already have an established practice of microdosing will come to the lab to complete a cutting-edge battery of measures.<\/p>\n<p>\u201cOur focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition,\u201d said Dr. Polito. \u201cIn exploring the experiences of genuine microdosers from multiple angles, looking at behavioural, neuroimaging and biomarker data, we want to discover what actually happens when people microdose \u2018in the wild\u2019 and whether we can find objective indicators of some of the benefits that microdosers claim.&#8221;<\/p>\n<p>The study will also be the first to use Magnetoencephalography, or MEG scans, to identify brain activity, along with planned cognitive and biometric measures, while microdosing.<\/p>\n<p>\u201cThis study will further shed light on currently ambiguous effects of microdosing,\u201d said Josh Bartch, CEO and Co-Founder of Mydecine. \u201cMicrodosing has a strong following of self-administering users, but actual medical data is currently thin. By applying scientific rigor like this, along with the ongoing work at the Imperial College London, we are helping to build a library of solid data sets that begin to tell us how microdosing works, and how it can be used in future clinical trials for various mental health issues.\u201d<\/p>\n<p>Dr. Polito is a Research Fellow in the Department of Cognitive Science at Macquarie University. His focus is on self representation and developing measures of how our sense of self changes in different contexts, clinical conditions, and altered states of consciousness.<\/p>\n<p>\n        <strong>About Mydecine Innovations Group<\/strong>\n      <\/p>\n<p>Mydecine Innovations Group\u2122 is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company\u2019s world-renowned medical and scientific advisory board is progressing a robust R&amp;D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import\/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada. Mydecine\u2019s portfolio companies Mydecine Health Sciences\u2122, Mindleap Health\u2122, and NeuroPharm\u2122 position the company at the forefront of disruptive modern medicine.<\/p>\n<p>Learn more at: https:\/\/www.mydecine.com\/ and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=76TmUC59GVtzwwYAfhqhU7tBuVV9pZ1GIe_igVINpA93oix-uVlC9hQhYEZsljzs3z8mBk9Y9niuMHRmDYK0QwxPo8Hz1vZqg1Kwx96guZE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Facebook<\/u><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P3ei0U3cabLKc-ESc6oEYz-Zq-pQ250372f9NIIhLFwdsnIM7r9FU8br6_PnIhoauy8Uuh4yrB5v4YlmbyX07g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Twitter<\/u><\/a>, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PqPnqa6OFNhzV_5f6pSENi_BaAdlllAX60gFPZqIhslmcKzZc4dEiVal0qj68qvTB_G_wROa_tnMY_9hS4Qj2JzZl2VzRDjIH1UOD0dk7eM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Instagram<\/u><\/a>.<\/p>\n<p>\n        <strong>Mydecine Innovations Group Media Contacts<\/strong><br \/>\n        <br \/>Anne Donohoe \/ Nick Opich<br \/>KCSA Strategic Communications<br \/>adonohoe@kcsa.com \/ nopich@kcsa.com<br \/>212-896-1265 \/ 212-896-1206<\/p>\n<p>\n        <strong>On behalf of the Board of Directors:<\/strong><br \/>\n        <br \/>Joshua Bartch, Chief Executive Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qqMpe1Eeg3vkwSRN7GTy0zyo0IMoC8RjxWF5xoMrUi3nrKW8upc1Bd9QZztfc5AX5J9qVfQoUSgqVz-JbcR7cdVp05oa_laVoPlijvnPayM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">contact@mydecineinc.com<\/a><\/p>\n<p>\n        <strong>Corp Communication:<\/strong><br \/>\n        <br \/>Charles Lee, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OA1FQjtFX75OLlPbY7VrnIgdcgGrsilaWVtZCat5wUE9HftWa353meUw22yAAotZtc5aHbyQkuNJ76mpJsm_0jxSWh8CIle5uyaoK-BER7Y=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">corp@mydecineinc.com<\/a><br \/>+1 720-277-9879<\/p>\n<p>\n        <strong>For further information about Mydecine Innovations Group, Inc., please visit the Company\u2019s profile on SEDAR at<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nZH1n3_6SmGA2XjHILmEsesEBdtZbfRyZQAIK93I_iRijzGffMophUc2gpMuvbnld-FnvBUCF7cNE48206AR_44To1CkUiZK2IaGAQmZI80p7tGT_ITv_-zpC0rcNxSXYCgCBjhRVebcoGa3wNQJTXsVy1lqZXubn-OQxNKpDEU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <strong>www.sedar.com<\/strong><br \/>\n        <\/a><br \/>\n        <strong> or visit the Company\u2019s website at<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qCmT6lgoOQIAMkyc3cddOxaNgnIjDD5Omt4ho_TbiESjUAdC5W6CAQ-AvZe144U1XCtIlxRz9vsAyhLfVMteRQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <strong>www.mydecine.com<\/strong><br \/>\n        <\/a><br \/>\n        <strong>.<\/strong>\n      <\/p>\n<p>\n        <strong>The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. <\/strong>This news release contains forward-looking statements, which relate to future events or future performance and reflect management\u2019s current expectations and assumptions. Such forward-looking statements reflect management\u2019s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company&#8217;s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company&#8217;s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f39e488f-2f60-4833-873e-298151817bee\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DENVER, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (\u201cMydecine\u201d or the \u201cCompany\u201d), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: \u201cThe neurocognitive effects of low dose psychoactive substances,\u201d at Australia\u2019s Macquarie University The research, led by Principal Investigator Dr. Vince Polito, Senior Research Fellow at the Department of Cognitive Science at Macquarie University, is the first study of naturalistic microdosing in a lab setting. Previous studies have either relied on surveys of microdosers or have given people who have not microdosed before a single controlled dose. In this study people &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408312","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DENVER, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (\u201cMydecine\u201d or the \u201cCompany\u201d), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: \u201cThe neurocognitive effects of low dose psychoactive substances,\u201d at Australia\u2019s Macquarie University The research, led by Principal Investigator Dr. Vince Polito, Senior Research Fellow at the Department of Cognitive Science at Macquarie University, is the first study of naturalistic microdosing in a lab setting. Previous studies have either relied on surveys of microdosers or have given people who have not microdosed before a single controlled dose. In this study people &hellip; Continue reading &quot;Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T12:33:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia\",\"datePublished\":\"2021-01-05T12:33:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/\"},\"wordCount\":957,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/\",\"name\":\"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU=\",\"datePublished\":\"2021-01-05T12:33:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/","og_locale":"en_US","og_type":"article","og_title":"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia - Market Newsdesk","og_description":"DENVER, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (\u201cMydecine\u201d or the \u201cCompany\u201d), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: \u201cThe neurocognitive effects of low dose psychoactive substances,\u201d at Australia\u2019s Macquarie University The research, led by Principal Investigator Dr. Vince Polito, Senior Research Fellow at the Department of Cognitive Science at Macquarie University, is the first study of naturalistic microdosing in a lab setting. Previous studies have either relied on surveys of microdosers or have given people who have not microdosed before a single controlled dose. In this study people &hellip; Continue reading \"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T12:33:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia","datePublished":"2021-01-05T12:33:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/"},"wordCount":957,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/","name":"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU=","datePublished":"2021-01-05T12:33:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDIzOCMzOTAzNzM1IzIyMDE0MjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408312"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408312\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}